Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

AIDS

Volumn 26, Issue 18, 2012, Pages 2285-2293

  Massanella, Marta ^a   Negredo, Eugènia ^a   Puig, Jordi ^a   Puertas, Maria C ^a   Buzón, Maria J ^a   Pérez Álvarez, Núria ^a   Carrillo, Jorge ^a   Clotet, Bonaventura ^a   Martínez Picado, Javier ^a,b   Blanco, Julià ^a,c  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

CD38; CD8 activation; cell death; human leukocyte antigen DR; immunodiscordance

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; HLA DR ANTIGEN; RALTEGRAVIR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GANCICLOVIR; HIV INFECTIONS; HUMANS; HYDROXYCHLOROQUINE; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLIDINONES; VIRAL LOAD;

EID: 84870242082     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359f20f     Document Type: Article

References (31)

1. Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-750. (Pubitemid 28190697)
2. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, et al. Mechanisms involved in the low-level regeneration of CD4R cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191:1670-1679. (Pubitemid 40656755)
3. Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, Bofill M, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010;24:959-968.
4. Gazzola L, Tincati C, Bellistrí GM, Monforte A, Marchetti G. The absence of CD4R T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009;48:328-337.
5. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011;117:5142-5151.
6. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010;50:1300-1308.
7. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011;204:1217-1226.
8. Merlini E, Bai F, Bellistrí GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011;6:e18580.
9. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011;203:1637-1646.
10. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011;203:452-463.
11. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4R T cell recovery on antiretroviral therapy. J Infect Dis 2011;203:1474-1483.
12. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological nonresponders. Blood 2011;118:3263-3272.
13. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010;7:e1000321.
14. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4R T cell response. J Infect Dis 2011;203:960-968.
15. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16:460-465.
16. Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012;17:355-364.
17. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004;18:1673-1682. (Pubitemid 39095784)
18. Blanco J, Barretina J, Clotet B, Esté JA. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004;76:804-811. (Pubitemid 39313716)
19. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371. (Pubitemid 44924494)
20. Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIVinfected patients with suboptimal CD4R T-cell response: a randomized controlled trial. J Infect Dis 2011;204:1532-1540.
21. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011;117:5582-5590.
22. Garrido C, Rallón N, Soriano V, Lopez M, Zahonero N, de Mendoza C, et al. Mechanisms involved in CD4 gains in HIVinfected patients switched to raltegravir. AIDS 2012;26:551-557.
23. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIVpositive adults on suppressive antiretroviral therapy. AIDS 2010;24:2451-2460.
24. Nadal M, Mas PJ, Mas PJ, Blanco AG, Arnan C, Solà M, et al. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc Natl Acad Sci U S A 2010;107:16078-16083.
25. Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, O'Rourke S, et al. CD8R lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLADRR CD38-CD8R cells is associated with subsequent stable CD4R cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 1994;170:775-781.
26. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Increased numbers of primed activated CD8RCD38R CD45RORT cells predict the decline of CD4RT cells in HIV-1-infected patients. AIDS 1996;10:827-834.
27. Rodriguez B, Lederman MM, Jiang W, Bazdar DA, Gàrate K, Harding CV, et al. Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. AIDS 2006;20:1379-1389. (Pubitemid 43948244)
28. Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, et al. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther 2010;15:333-342.
29. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, et al. Innate sensing of HIV-infected cells. PLoS Pathog 2011;7:e1001284.
30. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger S, Martinez R, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011;121:2391-2400.
31. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73:975-983.